Drugs / MEDI7510
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02289820 | Jan 2015 → Feb 2016 | respiratory syncytial virus infectious disease | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT02115815 | Apr 2014 → Jun 2015 | respiratory syncytial virus infectious disease | MedImmune LLC | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02508194 | Sep 2015 → Sep 2016 | respiratory syncytial virus infectious disease | MedImmune LLC | Terminated | Missed primary Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI7510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02289820 ↗ |
| Modality | Vaccine | “post hoc comparison of samples from the DS-Cav1 [prefusion (pre-F)] and MEDI7510 [postfusion (post-F)] vaccine clinical trials.” PMID 36542692 ↗ Dec 2022 |
| Route | Intramuscular | “by intramuscular injection” NCT02115815 ↗ |